Oligomerix
Dhruv Patel, Ph.D. is a Scientist at Oligomerix, Inc. with a strong background in neurobiochemistry and neuropharmacology. Dhruv previously worked as a Doctoral Candidate at Rush University, where Dhruv developed transgenic animal models of Alzheimer's disease. Patel also has experience as a Cellular and Molecular Biology Tutor at Hudson County Community College and as a Laboratory Technician at St John's University. Dhruv interned at Regeneron Pharmaceuticals and worked as a Quality Control and Research Associate at Hamax Pharmaceutical in India. With a Ph.D. in Biochemistry (Neuro Track) and a Master's in Biological and Pharmaceutical Biotechnology, Dhruv brings a wealth of knowledge and expertise to their current role.
This person is not in any offices
Oligomerix
Oligomerix is an emerging biotechnology company focused on developing disease-modifying therapeutics for Alzheimer’s disease and related dementias by targeting tau self-association. The company’s drug discovery platform has identified a pipeline of novel small molecule inhibitors, with preclinical IND-enabling studies in progress for the lead program. Oligomerix’s small molecule approach blocks the formation of all tau aggregates by targeting tau self-association, known as the beginning of the aggregation cascade, whereas other companies have focused on targeting large tau aggregates formed downstream. The NYC-based company is located at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine.